London Daily

Focus on the big picture.
Wednesday, Oct 01, 2025

What do we know about the Russian vaccine

What do we know about the Russian vaccine

Study findings on the Russian vaccine against Covid-19 show that it is safe, well tolerated and induces cellular immune responses in 100% of healthy participants.

This was published by The Lancet magazine, based on a preliminary study carried out by researchers from the Russian government. This study was evaluated by a rereading committee of the British medical journal prior to its publication.

All reported adverse events on the Russian vaccine were mostly mild. However, a comparative clinical study with other vaccines is needed to confirm these findings, the publication notes.


The information is released after the Russian authorities announced, last August, their vaccine against Covid-19, which they call Sputnik V, in honor of the first satellite launched into space, in 1957.

On August 11, it was reported that Sputnik V was entering the third and final phase of clinical trials.

What elements emerge from the article published in The Lancet? Sputnik V consists of two components: recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5); and that both rAd26 and rAd5 contain the SARS-CoV-2 virus protein S gene.

It should be explained that adenoviruses are a group of viruses that typically cause respiratory diseases, such as colds, conjunctivitis (eye infection), bronchiolitis, pneumonia, among others. Both components were developed, manufactured and stored by the National Research Center for Epidemiology and Microbiology NF Gamaleya (Moscow).

During vaccination, component 1 is introduced for the first time and, after three weeks, component 2. According to the evaluation of the developer, the immunity can last up to two years. Then you may need to vaccinate again. However, this remains to be explored in post-marketing studies, explained Vadim Tarasov, director of the Institute of Transmission Medicine and Biotechnology and head of the department of pharmacology at Ivan Sechenov University.

How were the studies done?

It was precisely at the Ivan Sechenov University that preclinical trials of two dosage forms of the Russian vaccine were carried out. The other place where the studies took place was at Burdenko Hospital.

Healthy adult volunteers (men and women), whose ages ranged from 18 to 60 years old, were enrolled for the Russian vaccine studies. Between June 18 and August 3, 2020, they enrolled 76 participants in the two studies Thus, in each study, 38 volunteers were vaccinated. More men than women participated in the study.

According to Tarasov, the study itself was carried out in two stages. One of them was the observation of volunteers for 14 days in isolation to prevent them from contracting the coronavirus infection. Once the observation was completed and it was confirmed that the volunteers did not have Covid-19, they were transported, with all possible precautions, to the cardioangiology center of the Ivan Sechenov University.

In this hospital, 38 volunteers stayed 28 days after the first injection of the drug and were discharged one week after the second. Their stay in the hospital was organized to protect them from the possibility of becoming infected and thus dropping out of the study or entering incorrect data on the immunity developed, he explained.

It was extremely important work, to reliably assess the response of the immune system and draw preliminary conclusions about the effectiveness of the drug, says Sechenov.

According to the study published in The Lancet, the most common reactions among participants were pain at the injection site, hyperthermia (body temperature 37–38 ° C), headache, fatigue, and muscle and joint pain. No serious adverse events were reported during the investigation.

Notably, the volunteers had no infectious diseases at the time of vaccination and for 14 days prior to vaccination, and did not receive any other vaccines within 30 days of participating in the study.

Caution

When the world announcement of Sputnik V was made, it was greeted with skepticism by many researchers by the scientific community. Its efficacy and safety were questioned, mainly due to the absence of public data on the trials conducted up to that point.

This opinion is largely due to misunderstanding that the preparation in question is registered in the Russian Federation 'conditionally', says Sechenov. As he explains, this is a well-known and widely used mechanism in the United States, the European Union, Japan and other countries with a developed regulatory system. Its essence lies in the fact that if it is necessary to put the drug into practice as soon as possible, for example, for orphan or oncological diseases, during epidemics, etc., and it is impossible to conduct full clinical trials, the drug is temporarily registered with indications of limited use, which are based on the results of clinical trials already carried out, he details.

At the same time, a mandatory requirement is to conduct post-registration studies with the participation of a certain number of patients at a given time, and any use of the drug becomes part of the study.

This is the case of the Sputnik V vaccine, whose registration certificate was issued until January 2021, and as a prerequisite, clinical trials with 40,000 participants were established, says Sechenov.

As has been announced, this will be the objective of the phase 3 trial (which will include 40,000 participants), of various ages and with different risk levels.

Since the announcement made by President Vladimir Putin last August, the World Health Organization (WHO) has urged Russia to follow the established protocol and comply with all the phases necessary to develop a safe vaccine.

The WHO will not endorse a vaccine against the coronavirus if it is not safe and effective, declared this Friday, September 4, its director general, Tedros Adhanom Ghebreyesus.

According to the WHO, there are 176 vaccine projects underway in the world, of which 34 are in the clinical trial phase, which means that they have started to be tested in humans. Among these, eight are in phase three, the most advanced.

Around the world, the pandemic has claimed so far the lives of more than 875,700 people and infected more than 26.6 million.


Newsletter

Related Articles

0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×